September 25th 2024
With art we build what poverty destroys.
The Role of Orexin Receptor 2 Agonists in Sleep and Narcolepsy Type 1
February 15th 2024Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
New Conference Series Focuses on Improving Mental Health Care for Black Youth
February 12th 2024Learn more about the inaugural Black Youth Mental Health Clinical Case Conference Series at Yale Child Study Center, a 6-session event in 2024, that focuses on improving mental health care for Black youth and their families.
New Data on Esketamine Nasal Spray as Treatment for Adolescents Contemplating Suicide
December 12th 2023These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.